COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts trial for Jaguar's crofelemer, plant-based drug granted Orphan Drug Designation. Study could lead to early patient access in Europe for rare diseases -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Napo Pharmaceuticals files provisional patent application with USPTO for crofelemer, a novel plant-based drug to mitigate GI side effects of GLP-1 therapies -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts Jaguar Health's crofelemer trial for MVID & SBS-IF. POC data aims to support early patient access in EU countries
